

Stanford



Minggui Pan, MD, PhD

Clinical Professor, Medicine - Oncology

CLINICAL OFFICE (PRIMARY)

900 Welch Rd
Suite 155
Palo Alto, CA 94305
Tel (408) 866-3800 **Fax** (408) 866-3858

Bio

BIO

Dr. Pan is a board-certified, fellowship-trained medical oncologist with the Stanford Medicine Cancer Center and a clinical professor in the Department of Medicine, Division of Oncology.

He diagnoses and treats various oncological conditions and specializes in the treatment of bone and soft tissue sarcoma. He creates personalized and comprehensive care plans for each patient he serves.

Dr. Pan's research focuses include understanding how genomic alterations impact the biological behavior and prognosis of sarcomas. In his work, he identifies new targets for developing innovative therapeutics for sarcoma treatment.

He has published more than fifty papers and many abstracts and presented in many cancer and immunology conferences. His papers have been published in the Journal of Clinical Oncology, JCO Precision Oncology, Clinical Cancer Research, Nature Review Clinical Oncology, JCO Oncology Practice, Journal of Hematology and Oncology, and other peer-reviewed journals. He has also presented to his peers at international, national, and regional meetings, including the annual meetings of American Society of Clinical Oncology, Chinese Society Of Clinical Oncology, Connective Tissue Oncology Society and others.

Dr. Pan is a member of American Society of Clinical Oncology, American Association of Immunologists, American Association for Advancement of Science, Society for Immunotherapy of Cancer, and Connective Tissue Oncology Society. Dr. Pan is also an adjunct investigator with Kaiser Permanente Division of Research.

CLINICAL FOCUS

- Medical Oncology
- sarcoma
- clinical trial
- soft tissue sarcoma
- clear cell sarcoma

- endometrial stromal sarcoma
- alveolar soft part sarcoma
- desmoid tumor
- giant cell tumor
- chondrosarcoma
- Ewing sarcoma
- osteosarcoma
- liposarcoma
- leiomyosarcoma
- undifferentiated pleomorphic sarcoma
- gastrointestinal stromal tumor
- angiosarcoma

ACADEMIC APPOINTMENTS

- Clinical Professor, Medicine - Oncology
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Member, ASCO SEP Writing Task Force, (2019- present)
- Member, ASCO Workforce Advisory Group, (2014-2019)
- Adjunct Investigator, Kaiser Permanente Division of Research, (2015- present)

HONORS AND AWARDS

- Fellow of Lymphoma Research, Lymphoma Research Foundation of America (2000)
- Research Award, Cure for Lymphoma Foundation (2001)
- Merit Award, American Association of Clinical Oncology (2002)
- Young Investigator Award, American Society of Clinical Oncology (2002)
- Outstanding Achievement Award, The Permanente Medical Group (2010)
- Sidney Garfield Award for Exceptional Contributions, The Permanente Medical Group (2012)
- Asian Pacific Heritage Award, Kaiser Permanente (2013)
- Outstanding Teaching and Services Award, Veterans Healthcare Administration Palo Alto Section of Oncology, Stanford University (2013)
- The Morris F. Collen Research Award, The Permanente Medical Group (2023)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Member, Connective Tissue Oncology Society (2013 - present)
- Member, Society for Immunotherapy of Cancer (2023 - present)
- Member, American Association of Immunologists (2007 - present)
- Member, American Society of Clinical Oncology (1998 - present)
- Editorial Board, Journal of Hematology and Oncology (2023 - present)

PROFESSIONAL EDUCATION

- Board Certification: Medical Oncology, American Board of Internal Medicine (2001)

- Medical Education: Fujian Medical University (1984) China
- MS, Peking Union Medical College, Chinese Academy of Medical Sciences , Medicine (1989)
- PhD, Oregon Health Sciences University , Molecular and Cellular Biology (1994)
- Residency: St Mary's Medical Center Internal Medicine Residency CA
- Fellowship: Stanford University Hematology and Oncology Fellowship (2002) CA

COMMUNITY AND INTERNATIONAL WORK

- President

Research & Scholarship

CLINICAL TRIALS

- A Study of NB003 in Patients With Advanced Malignancies, Recruiting
- Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1), Recruiting
- Study of Cryoablation and Nirogacestat for Desmoid Tumor, Recruiting

Publications

PUBLICATIONS

- **PTEN pathogenic variants are associated with poor prognosis in patients with advanced soft tissue sarcoma** (<https://www.nature.com/articles/s44276-023-00029-3>) *BJC Reports*
Pan, M., Zhou, M., Jiang, C., Zhang, Z., Bui, N., Bien, J., Siy, A., Achacoso, N., Solorzano, A., Tse, P., Chung, E., Hu, W., Thomas, et al
2024
- **Sex-Dependent Prognosis of Patients with Advanced Soft Tissue Sarcoma.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Pan, M., Zhou, M. Y., Jiang, C., Zhang, Z., Bui, N. Q., Bien, J., Siy, A., Achacoso, N., Solorzano, A. V., Tse, P., Chung, E., Thomas, S., Habel, et al
2023
- **High-dimensional single-cell analysis unveils distinct immune signatures of peripheral blood in patients with pancreatic ductal adenocarcinoma** *FRONTIERS IN ENDOCRINOLOGY*
Pan, Y., Gao, J., Lin, J., Ma, Y., Hou, Z., Lin, Y., Wen, S., Pan, M., Lu, F., Huang, H.
2023; 14: 1181538
- **Treatment of De-Differentiated Liposarcoma in the Era of Immunotherapy.** *International journal of molecular sciences*
Zhou, M. Y., Bui, N. Q., Charville, G. W., Ganjoo, K. N., Pan, M.
2023; 24 (11)
- **Sex- and Co-Mutation-Dependent Prognosis in Patients with SMARCA4-Mutated Malignancies.** *Cancers*
Pan, M., Jiang, C., Zhang, Z., Achacoso, N., Solorzano-Pinto, A. V., Tse, P., Chung, E., Suga, J. M., Thomas, S., Habel, L. A.
2023; 15 (10)
- **TP53 Gain-of-Function and Non-Gain-of-Function Mutations Are Associated With Differential Prognosis in Advanced Pancreatic Ductal Adenocarcinoma.** *JCO precision oncology*
Pan, M., Jiang, C., Zhang, Z., Achacoso, N., Alexeef, S., Solorzano, A. V., Tse, P., Chung, E., Sundaresan, T., Suga, J. M., Thomas, S., Habel, L. A.
2023; 7: e2200570
- **Genomic, clinical characteristics, and treatment outcomes of patients with metastatic castration-sensitive prostate cancer with SPOP mutations: Analysis from the Kaiser Permanente Northern California Healthcare System.**
Thomas, S. P., Arora, A., Huang, H. X., Jiang, C., Chung, E., Suga, J., Sundaresan, T., Truong, T., Pan, M., Harzstark, A.
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Pain as Initial Presenting Symptom Is Associated With Delay to Seeking Medical Attention, Higher Risk of Relapse, and Shorter Survival in Patients With Early-Stage Extremity or Trunk Synovial Sarcoma.** *The Permanente journal*
Seto, T., Merchant, M., Morse, L. J., Fang, A., Song, M. N., Russell, E. A., Pan, M.

2022; 26 (3): 94-102

● **Prolonged disease control with pazopanib following radiation of primary tumor for locally advanced and metastatic soft tissue sarcoma.**

Pan, M., Yu, J. C., Sidhu, M.

LIPPINCOTT WILLIAMS & WILKINS.2022

● **Clinical benefit of imatinib in patients with relapsed tenosynovial giant cell tumor/ pigmented villonodular synovitis (TGCT/PVNS).**

Yu, J., Sidhu, M., Fang, A., Morse, L., Pan, M.

LIPPINCOTT WILLIAMS & WILKINS.2022

● **TP53 gain-of-function mutations and impact on CDKN2A mutation on prognosis of pancreatic ductal adenocarcinoma.**

Pan, M., Jiang, C., Zhang, Z., Achacoso, N., Tse, P., Solorzano, A., Chung, E., Sundaresan, T., Suga, J., Huang, J., Thomas, S. P., Habel, L. A.

LIPPINCOTT WILLIAMS & WILKINS.2022: E16294

● **TP53 Gain-of-Function and Non-Gain-of-Function Mutations Are Differentially Associated With Sidedness-Dependent Prognosis in Metastatic Colorectal Cancer** *JOURNAL OF CLINICAL ONCOLOGY*

Pan, M., Jiang, C., Tse, P., Achacoso, N., Alexeef, S., Solorzano, A., Chung, E., Hu, W., Truong, T., Arora, A., Sundaresan, T., Suga, J., Thomas, et al

2022; 40 (2): 171-+

● **Impact of a Virtual Multidisciplinary Sarcoma Case Conference on Treatment Plan and Survival in a Large Integrated Healthcare System** *JCO ONCOLOGY PRACTICE*

Pan, M., Yu, J., Sidhu, M., Seto, T., Fang, A.

2021; 17 (11): 681-+

● **Differential impact of different TP53 gain-of-function mutations on overall survival of patients with metastatic colorectal cancer: Results from a large integrated healthcare system.**

Pan, M., Jiang, C., Tse, P., Chung, E., Solorzano, A., Hu, W., Truong, T., Arora, A., Sundaresan, T., Suga, J., Habel, L. A., Thomas, S. P.

LIPPINCOTT WILLIAMS & WILKINS.2021

● **Association of TP53 mutation with decreased prevalence of MSI-high, RAS and PI3KCA mutations in metastatic colorectal cancer.**

Pan, M., Jiang, C., Tse, P., Solorzano-Pinto, A. V., Chung, E., Truong, T., Arora, A., Sundaresan, T., Suga, J., Habel, L. A., Thomas, S. P.

LIPPINCOTT WILLIAMS & WILKINS.2021

● **Rapid Response of a BRCA2/TP53/PTEN-Deleted Metastatic Uterine Leiomyosarcoma to Olaparib: A Case Report.** *The Permanente journal*

Pan, M., Ganjoo, K., Karam, A.

2021; 25

● **Fourteen-Day Gemcitabine-Docetaxel Chemotherapy Is Effective and Safer Compared to 21-Day Regimen in Patients with Advanced Soft Tissue and Bone Sarcoma** *CANCERS*

Pan, M., Trieu, M. K., Sidhu, M., Yu, J., Seto, T., Ganjoo, K.

2021; 13 (8)

● **Complete Regression of Rhabdomyosarcoma in an Adult Secondary to Postoperative Wound Infection Following Limb Salvage Surgery: A Case Report.** *The Permanente journal*

Fang, A. S., Morse, L. J., Wustrack, R., Huber, R., Pan, M.

2020; 25: 1

● **Feasibility and Value of Establishing a Community-Based Virtual Multidisciplinary Sarcoma Case Conference.** *JCO oncology practice*

Pan, M., Seto, T., Yu, J., Sidhu, M., Kim, B., McCormick, C., Fang, A., Song, J., Morse, L. J., Peng, P. D., Chakedis, J., Huber, R., Schwartz, et al

2020: OP2000110

● **Prevalence of delay to seeking medical attention in patients with synovial sarcoma and association with inferior outcomes.**

Seto, T., Song, M., Russell, E., Sam, D., Pan, M.

LIPPINCOTT WILLIAMS & WILKINS.2020

● **The impact of tumor NGS testing on hereditary cancer risk assessment and population management in an integrated community health care system.**

Thomas, S. P., Suga, J., Thach-Giao Truong, Sundaresan, T., Pan, M., Kim, W., Jiang, C., Hoodfar, E., Chung, E., Tse, P., Achacoso, N., Cheng, L., Habel, L. A.

LIPPINCOTT WILLIAMS & WILKINS.2020

● **Implementing a genomic oncology program in an integrated health care network with large scale genomic Next Generation Sequencing (NGS) testing of advanced cancers in a community setting.**

Suga, J., Thomas, S. P., Thach-Giao Truong, Sundaresan, T., Pan, M., Kim, W., Hoodfar, E., Cheng, L., Chung, E., Tse, P., Achacoso, N., Jiang, C., Goldstein, D., et al
LIPPINCOTT WILLIAMS & WILKINS.2020

- **Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer** *JOURNAL OF HEMATOLOGY & ONCOLOGY*
Pan, Y., Lu, F., Fei, Q., Yu, X., Xiong, P., Yu, X., Dang, Y., Hou, Z., Lin, W., Lin, X., Zhang, Z., Pan, M., Huang, et al
2019; 12 (1): 124
- **Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib** *ANTI-CANCER DRUGS*
Wang, S. Y., Zhang, B. M., Wakelee, H. A., Koontz, M. Z., Pan, M., Diehn, M., Kunder, C. A., Neal, J. W.
2019; 30 (5): 537–41
- **Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1** *ONCOIMMUNOLOGY*
Pan, Y., Fei, Q., Xiong, P., Yang, J., Zhang, Z., Lin, X., Pan, M., Lu, F., Huang, H.
2019; 8 (5): e1581529
- **Germline BRCA1 Deletion as Driver Mutation for Metastatic Urachal Adenocarcinoma in Patient Who Achieved Complete Response to Rucaparib.** *Journal of oncology practice*
Seto, T., Pujare, D., Song, M. N., Lee, J., Huber, R., Sam, D., Pan, M.
2019; 15 (5): 293-295
- **Real-World Experiences with Pazopanib in Patients with Advanced Soft Tissue and Bone Sarcoma in Northern California.** *Medical sciences (Basel, Switzerland)*
Seto, T., Song, M. N., Trieu, M., Yu, J., Sidhu, M., Liu, C. M., Sam, D., Pan, M.
2019; 7 (3)
- **Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer.** *Medical sciences (Basel, Switzerland)*
Seto, T., Sam, D., Pan, M.
2019; 7 (2)
- **WIPF1 antagonizes the tumor suppressive effect of miR-141/200c and is associated with poor survival in patients with PDAC** *JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH*
Pan, Y., Lu, F., Xiong, P., Pan, M., Zhang, Z., Lin, X., Pan, M., Huang, H.
2018; 37: 167
- **Association of Inflammatory Markers with Disease Progression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors.** *The Permanente journal*
Pan, M., Alavi, M., Herrinton, L. J.
2018; 22: 17-149
- **Risk Factors Including Age, Stage and Anatomic Location that Impact the Outcomes of Patients with Synovial Sarcoma.** *Medical sciences (Basel, Switzerland)*
Pan, M., Merchant, M.
2018; 6 (1)
- **Histologic Grade Is Predictive of Incidence of Epidermal Growth Factor Receptor Mutations in Metastatic Lung Adenocarcinoma.** *Medical sciences (Basel, Switzerland)*
Levy, M., Lyon, L., Barbero, E., Wong, J., Suga, M., Sam, D., Pan, M.
2017; 5 (4)
- **Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials.** *Pancreas*
Kunz, P. L., Balise, R. R., Fehrenbacher, L., Pan, M., Venook, A. P., Fisher, G. A., Tempero, M. A., Ko, A. H., Korn, W. M., Hwang, J., Bergsland, E. K.
2016; 45 (10): 1394-1400
- **Understanding Teamwork in the Provision of Cancer Care: Highlighting the Role of Trust** *JOURNAL OF ONCOLOGY PRACTICE*
Lazzara, E. H., Keebler, J. R., Day, S., DiazGranados, D., Pan, M., King, M. A., Tu, S.
2016; 12 (11): 1084-+
- **Improving care quality for patients with soft tissue and bone sarcoma by establishing a national virtual tumor board and electronic consultation platform.**
Pan, M., Fang, A., Kavanagh, M., Kim, B., Lee, J. D., McCormick, C., Morse, L., Nag, S., Nybbaken, G., Peng, P., Schwartz, C. M., Song, J., Taggart, et al

AMER SOC CLINICAL ONCOLOGY.2016

- **Study of Arsenic Sulfide in Solid Tumor Cells Reveals Regulation of Nuclear Factors of Activated T-cells by PML and p53** *SCIENTIFIC REPORTS*
Ding, W., Tong, Y., Zhang, X., Pan, M., Chen, S.
2016; 6: 19793
- **Arsenic sulfide combined with JQ1, chemotherapy agents, or celecoxib inhibit gastric and colon cancer cell growth** *DRUG DESIGN DEVELOPMENT AND THERAPY*
Zhang, L., Tong, Y., Zhang, X., Pan, M., Chen, S.
2015; 9: 5851-5861
- **Activation of NFAT signaling establishes a tumorigenic microenvironment through cell autonomous and non-cell autonomous mechanisms** *ONCOGENE*
Tripathi, P., Wang, Y., Coussens, M., Manda, K. R., Casey, A. M., Lin, C., Poyo, E., Pfeifer, J. D., Basappa, N., Bates, C. M., Ma, L., Zhang, H., Pan, et al
2014; 33 (14): 1840-1849
- **Efficacy and Safety Profile of Combining Vandetanib with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer: A Meta-Analysis** *PLOS ONE*
Tian, W., Ding, W., Kim, S., Zheng, L., Zhang, L., Li, X., Gu, J., Zhang, L., Pan, M., Chen, S.
2013; 8 (7): e67929
- **Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: A meta-analysis** *PANCREATOLOGY*
Tian, W., Ding, W., Kim, S., Xu, X., Pan, M., Chen, S.
2013; 13 (4): 415-422
- **NFAT Gene Family in Inflammation and Cancer** *CURRENT MOLECULAR MEDICINE*
Pan, M., Xiong, Y., Chen, F.
2013; 13 (4): 543-554
- **Brg1 governs a positive feedback circuit in the hair follicle for tissue regeneration and repair.** *Developmental cell*
Xiong, Y., Li, W., Shang, C., Chen, R. M., Han, P., Yang, J., Stankunas, K., Wu, B., Pan, M., Zhou, B., Longaker, M. T., Chang, C.
2013; 25 (2): 169-181
- **Conditional NFAT activation promotes prostate oncogenesis through cell autonomous and non-cell autonomous effects**
Manda, K., Tripathi, P., Wang, Y., Humphrey, P. A., Pan, M., Chen, F.
AMER ASSOC CANCER RESEARCH.2013
- **Brg1 governs distinct pathways to direct multiple aspects of mammalian neural crest cell development** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Li, W., Xiong, Y., Shang, C., Twu, K. Y., Hang, C. T., Yang, J., Han, P., Lin, C., Lin, C., Tsai, F., Stankunas, K., Meyer, T., Bernstein, et al
2013; 110 (5): 1738-1743
- **Improving detection of Lynch syndrome using a reflex immunohistochemistry algorithm for all patients with newly diagnosed colorectal cancer**
Pan, M., Hoodfar, E., Bergoffen, J., Fulton, R., Hofmeister, L., Chavez, A., Li, D.
AMER SOC CLINICAL ONCOLOGY.2012
- **Impact of early engagement of patients with clinical trial information in a system-based multidisciplinary breast cancer clinic on clinical trial enrollment**
Pan, M., Lee, A. C., Seaward, S. A., Ilano, A., House, K., Duran, E., DuLong, M., Kavanagh, M.
AMER SOC CLINICAL ONCOLOGY.2012
- **Activation of NFAT Signaling in Podocytes Causes Glomerulosclerosis** *JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY*
Wang, Y., Jarad, G., Tripathi, P., Pan, M., Cunningham, J., Martin, D. R., Liapis, H., Miner, J. H., Chen, F.
2010; 21 (10): 1657-1666
- **Phase II trial of 21-day regimen of irinotecan and carboplatin for chemonaive or relapsed small-cell lung cancer: Long-term survival**
Chen, G. Q., Huynh, M., Fehrenbacher, L., Davies, A. M., West, H., Gordon, P., Pan, M., Russin, M., Lara, P. N., Gandara, D. R., Lau, D. H.
AMER SOC CLINICAL ONCOLOGY.2008
- **CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation** *NATURE CLINICAL PRACTICE ONCOLOGY*
Pan, M., Santamaria, M., Wollman, D. B.
2007; 4 (10): 603-607

- Enhanced NFATc1 nuclear occupancy causes T cell activation independent of CD28 costimulation *JOURNAL OF IMMUNOLOGY*
Pan, M., Winslow, M. M., Chen, L., Kuo, A., Felsher, D., Crabtree, G. R.
2007; 178 (7): 4315-4321
- Stringent control of NFATc1 nuclear occupancy is critical for maintaining balanced immune response *GENE THERAPY AND MOLECULAR BIOLOGY*
Pan, M., Winslow, M. M., Keum, J. S., Crabtree, G. R.
2007; 11B: 171-176
- Calcineurin/NFAT signaling in osteoblasts regulates bone mass *DEVELOPMENTAL CELL*
Winslow, M. M., Pan, M., Starbuck, M., Gallo, E. M., Deng, L., Karsenty, G., Crabtree, G. R.
2006; 10 (6): 771-782
- Overexpression of EphA2 gene in invasive human breast cancer and its association with hormone receptor status.
Pan, M.
AMER SOC CLINICAL ONCOLOGY.2005: 857S
- Brg1, a chromatin remodeling gene, is suppressed in ER-negative breast cancer in human.
Pan, M.
SPRINGER.2005: S186
- cAMP activates MAP kinase and Elk-1 through a B-Raf- and Rap1-dependent pathway *CELL*
Vossler, M. R., Yao, H., York, R. D., Pan, M. G., Rim, C. S., Stork, P. J.
1997; 89 (1): 73-82
- TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways *CELL*
Hsu, H. L., Shu, H. B., Pan, M. G., Goeddel, D. V.
1996; 84 (2): 299-308
- Sequence, genomic organization, and chromosome localization of the mouse TRADD gene *JOURNAL OF INFLAMMATION*
Pan, M. G., Xiong, J., Copeland, N. G., Gilbert, D. J., Jenkins, N. A., Goeddel, D. V.
1996; 46 (3): 168-175
- The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral-inhibitor of apoptosis proteins *CELL*
Rothe, M., Pan, M. G., Henzel, W. J., Ayres, T. M., Goeddel, D. V.
1995; 83 (7): 1243-1252
- The Wnt-1 proto-oncogene regulates MAP kinase activation by multiple growth factors in PC12 cells. *Oncogene*
Pan, M. G., Wang, Y. H., Hirsch, D. D., Labudda, K., Stork, P. J.
1995; 11 (10): 2005-12
- Cloning and expression of two structurally distinct receptor-linked protein-tyrosine phosphatases generated by RNA processing from a single gene. *The Journal of biological chemistry*
Pan, M. G., Rim, C., Lu, K. P., Florio, T., Stork, P. J.
1993; 268 (26): 19284-91
- DOPAMINERGIC INHIBITION OF DNA-SYNTHESIS IN PITUITARY-TUMOR CELLS IS ASSOCIATED WITH PHOSPHOTYROSINE PHOSPHATASE-ACTIVITY *JOURNAL OF BIOLOGICAL CHEMISTRY*
FLORIO, T., PAN, M. G., NEWMAN, B., HERSHBERGER, R. E., CIVELLI, O., STORK, P. J.
1992; 267 (34): 24169-24172
- G-PROTEIN ACTIVATION OF A HORMONE-STIMULATED PHOSPHATASE IN HUMAN TUMOR-CELLS *SCIENCE*
PAN, M. G., FLORIO, T., STORK, P. J.
1992; 256 (5060): 1215-1217
- [Effect of low protein diet, plus essential amino acids on lipid metabolism in patients with chronic renal failure]. *Zhonghua nei ke za zhi*
Bi, Z. Q., Pan, M. G., Cheng, B. S.
1991; 30 (2): 69-72, 124